| Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96 … A Gajjar, M Chintagumpala, D Ashley, S Kellie, LE Kun, TE Merchant, ... The lancet oncology 7 (10), 813-820, 2006 | 1034 | 2006 |
| Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/− p53−/− mice JT Romer, H Kimura, S Magdaleno, K Sasai, C Fuller, H Baines, ... Cancer cell 6 (3), 229-240, 2004 | 630 | 2004 |
| Mrp4 confers resistance to topotecan and protects the brain from chemotherapy M Leggas, M Adachi, GL Scheffer, D Sun, P Wielinga, G Du, KE Mercer, ... Molecular and cellular biology 24 (17), 7612-7621, 2004 | 519 | 2004 |
| Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy PV Dickson, JB Hamner, TL Sims, CH Fraga, CYC Ng, S Rajasekeran, ... Clinical cancer research 13 (13), 3942-3950, 2007 | 500 | 2007 |
| Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032 GW Robinson, BA Orr, G Wu, S Gururangan, T Lin, I Qaddoumi, ... Journal of Clinical Oncology 33 (24), 2646, 2015 | 465 | 2015 |
| Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. J Lian, C Stewart, E Puchacz, S Mackowiak, V Shalhoub, D Collart, ... Proceedings of the National Academy of Sciences 86 (4), 1143-1147, 1989 | 447 | 1989 |
| Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro PJ Houghton, GS Germain, FC Harwood, JD Schuetz, CF Stewart, ... Cancer research 64 (7), 2333-2337, 2004 | 424 | 2004 |
| Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, ... The lancet oncology 20 (7), 1011-1022, 2019 | 397 | 2019 |
| A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study A Banerjee, RI Jakacki, A Onar-Thomas, S Wu, T Nicolaides, ... Neuro-oncology 19 (8), 1135-1144, 2017 | 308 | 2017 |
| Medulloblastoma genotype dictates blood brain barrier phenotype TN Phoenix, DM Patmore, S Boop, N Boulos, MO Jacus, YT Patel, ... Cancer cell 29 (4), 508-522, 2016 | 303 | 2016 |
| Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors PJ Houghton, PJ Cheshire, L Myers, CF Stewart, TW Synold, ... Cancer chemotherapy and pharmacology 31 (3), 229-239, 1992 | 285 | 1992 |
| Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children WL Furman, CF Stewart, CA Poquette, CB Pratt, VM Santana, ... Journal of clinical oncology 17 (6), 1815-1815, 1999 | 274 | 1999 |
| A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation B Thiessen, C Stewart, M Tsao, S Kamel-Reid, P Schaiquevich, W Mason, ... Cancer chemotherapy and pharmacology 65, 353-361, 2010 | 237 | 2010 |
| Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice CF Stewart, M Leggas, JD Schuetz, JC Panetta, PJ Cheshire, J Peterson, ... Cancer research 64 (20), 7491-7499, 2004 | 228 | 2004 |
| Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study A Gajjar, CF Stewart, DW Ellison, S Kaste, LE Kun, RJ Packer, S Goldman, ... Clinical Cancer Research 19 (22), 6305-6312, 2013 | 227 | 2013 |
| Crenolanib is active against models of drug-resistant FLT3-ITD− positive acute myeloid leukemia EI Zimmerman, DC Turner, J Buaboonnam, S Hu, S Orwick, MS Roberts, ... Blood, The Journal of the American Society of Hematology 122 (22), 3607-3615, 2013 | 209 | 2013 |
| Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial GW Robinson, VA Rudneva, I Buchhalter, CA Billups, SM Waszak, ... The Lancet Oncology 19 (6), 768-784, 2018 | 208 | 2018 |
| Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report M Fouladi, JR Park, CF Stewart, RJ Gilbertson, P Schaiquevich, J Sun, ... Journal of Clinical Oncology 28 (22), 3623, 2010 | 200 | 2010 |
| Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels S Zhou, Y Zong, PA Ney, G Nair, CF Stewart, BP Sorrentino Blood 105 (6), 2571-2576, 2005 | 193 | 2005 |
| Phase I study of everolimus in pediatric patients with refractory solid tumors M Fouladi, F Laningham, J Wu, MA O'Shaughnessy, K Molina, ... Journal of clinical oncology 25 (30), 4806-4812, 2007 | 187 | 2007 |
Sharyn BakerThe Ohio State UniversityVerified email at osu.edu
